Published in Hepatitis Weekly, June 24th, 2002
IFN and ribavirin combination therapy has become a mainstay for treating patients with chronic hepatitis C who are infected with hepatitis C virus (HCV) genotype 1. However, a fair number of patients who are prescribed combination therapy often won't demonstrate a sustained response when treatment ends, or after demonstrating a response, will relapse.
According to researchers in Rome, Italy, a genetically...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly